Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LHNVD-202
- Development stage
- Preclinical
- Lead developer
- Longhorn Vaccines and Diagnostics
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
LHNVD-202 is a synthetic peptide vaccine developed by Longhorn Vaccines & Diagnostics. It is designed as a dual peptide universal vaccine candidate targeting both influenza and SARS-CoV-2 (COVID-19). The vaccine comprises unconjugated composite peptides that include epitopes from highly conserved regions of influenza virus proteins (such as hemagglutinin, neuraminidase, and matrix protein) and the RNA polymerase of SARS-CoV-2. Preclinical data suggest that LHNVD-202 induces broadly reactive and durable antibody responses against multiple strains of both viruses. The primary indications are for the prevention of COVID-19 and human influenza infection[1][2].
02
Targets
HA0 (Influenza B virus hemagglutinin)M2e (Influenza A matrix protein 2 ectodomain)NeuraminidaseSevere acute respiratory syndrome coronavirus 2 spike glycoprotein conserved epitopesHA (Hemagglutinin)M1 (Muscarinic acetylcholine receptor M1)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on LHNVD-202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LHNVD-202.